Aussie scientists raise doubts over vaccine efficacy of AstraZeneca

Aussie scientists raise doubts over vaccine efficacy of AstraZeneca

The company has said it will sell it for $2.50 a dose and plans to make up to 3 billion doses by the end of 2021.

Crucially, the AstraZeneca vaccine is just one of the four the Australian government has entered into agreements to secure.

The Amsterdam-based regulator said that its assessment of the vaccine would "proceed under an accelerated timeline".

The prime minister said a huge network of 233 hospitals, 1,000 GP surgeries, 200 pharmacies and 50 mass vaccination centres is already working "exceptionally fast", but "at the moment the limit is on supply" of the vaccine.

A year ago leading medical journal, The Lancet, reported the efficacy for the Oxford-AstraZeneca COVID-19 vaccine was 62.1 percent with two standard doses of the vaccine.

Chief Medical Officer Professor Paul Kelly said the current Novavax Phase Three trial involving 30,000 participants in the United States was showing a "very strong performance" much "quicker" than expected.

In terms of efficacy, the Pfizer vaccine protects 94.5% of people from developing COVID.

The EU has sealed six vaccine contracts for up to 2 billion doses, many more than are necessary to cover its population of approximately 450 million.

On Sunday, federal Chief Medical Officer Professor Paul Kelly said most Australians will be offered a vaccine from Oxford-AstraZeneca.

AstraZeneca COVID-19 vaccine
The European Medicines Agency has received authorisation papers for the Astra Zeneca COVID-19 vaccine. Pic Artur Widak Nur

More studies are underway to define this and the Therapeutic Goods Administration, Australia's regulatory body, will evaluate new data as it comes through.

"So I can firmly confirm that the pressure that we have been under his pressure or responsibility towards European citizens, not political pressure".

The head of the Oxford Vaccine Group, Andrew Pollard, told the ABC the impact of vaccines was not determined by efficacy during clinical trials, but "when they're in people's arms".

However, Professor O'Neill reassured people that's still a very effective rate.

The second dose of coronavirus vaccines are now being given three months later than originally planned to ensure more people are given a first dose to help fight the UK's rising COVID-19 infection rate.

"Since the start of this pandemic, and I can speak from the start of my tenure at EMA, we have been looking at ways to take out the more bureaucratic aspects of our processes, to try and make sure that we have a robust scientific process at the same time as eliminating things that might be unnecessary". "The pooled (efficacy) result was 70 per cent".

According to him, the authorities' choice is not that "one is better than the other".

We all stand to benefit from a strategy that protects extremely vulnerable groups from severe disease and aims to rapidly generate immunity in the rest of our community.

Related Articles